Alfen NV
AEX:ALFEN
Alfen NV
AEX:ALFEN
Price:
9.42
EUR
-1.87%
Market Closed
Market Cap:
€204.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Alfen NV
AEX:ALFEN
|
NL |
|
P
|
PT Nusantara Sawit Sejahtera Tbk
IDX:NSSS
|
ID |
|
Tatva Chintan Pharma Chem Ltd
NSE:TATVA
|
IN |
|
Rubis SCA
LSE:0RTS
|
FR |
|
A
|
Arthur J. Gallagher & Co.
SWB:GAH
|
US |
Balance Sheet
Balance Sheet Decomposition
Alfen NV
Alfen NV
Balance Sheet Decomposition is not available for
Alfen NV
Alfen NV
Balance Sheet
Alfen NV
Alfen NV
Currency: EUR
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
1
|
1
|
0
|
1
|
0
|
52
|
47
|
23
|
2
|
17
|
27
|
|
| Cash Equivalents |
1
|
1
|
0
|
1
|
0
|
52
|
47
|
23
|
2
|
17
|
27
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
26
|
0
|
0
|
|
| Total Receivables |
9
|
11
|
18
|
29
|
34
|
36
|
62
|
108
|
136
|
133
|
97
|
|
| Accounts Receivables |
7
|
7
|
0
|
19
|
24
|
24
|
47
|
71
|
79
|
88
|
56
|
|
| Other Receivables |
2
|
4
|
0
|
10
|
10
|
12
|
15
|
36
|
57
|
45
|
41
|
|
| Inventory |
2
|
4
|
3
|
10
|
14
|
20
|
42
|
132
|
151
|
102
|
82
|
|
| Total Current Assets |
13
|
16
|
21
|
40
|
49
|
109
|
151
|
262
|
315
|
251
|
205
|
|
| PP&E Net |
2
|
3
|
4
|
7
|
16
|
24
|
25
|
34
|
53
|
84
|
74
|
|
| PP&E Gross |
2
|
3
|
0
|
7
|
16
|
24
|
25
|
34
|
53
|
84
|
74
|
|
| Accumulated Depreciation |
6
|
7
|
0
|
8
|
11
|
11
|
15
|
22
|
30
|
43
|
59
|
|
| Intangible Assets |
2
|
3
|
4
|
9
|
11
|
13
|
18
|
23
|
28
|
27
|
32
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
18
N/A
|
23
+30%
|
29
+29%
|
56
+91%
|
77
+36%
|
147
+91%
|
194
+33%
|
321
+65%
|
396
+23%
|
363
-8%
|
313
-14%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
8
|
10
|
19
|
22
|
27
|
27
|
48
|
72
|
75
|
69
|
20
|
|
| Short-Term Debt |
0
|
0
|
1
|
8
|
3
|
0
|
0
|
0
|
6
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
3
|
4
|
5
|
5
|
6
|
32
|
8
|
9
|
|
| Other Current Liabilities |
3
|
5
|
0
|
8
|
15
|
23
|
27
|
75
|
77
|
73
|
77
|
|
| Total Current Liabilities |
12
|
15
|
20
|
41
|
49
|
54
|
80
|
152
|
191
|
150
|
106
|
|
| Long-Term Debt |
1
|
2
|
2
|
7
|
12
|
15
|
14
|
13
|
19
|
42
|
39
|
|
| Deferred Income Tax |
1
|
1
|
1
|
2
|
2
|
3
|
4
|
6
|
7
|
1
|
1
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
18
|
14
|
|
| Total Liabilities |
14
N/A
|
18
+31%
|
23
+27%
|
49
+117%
|
64
+29%
|
72
+14%
|
98
+35%
|
170
+74%
|
216
+27%
|
211
-3%
|
160
-24%
|
|
| Equity | ||||||||||||
| Common Stock |
0
|
0
|
0
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Retained Earnings |
0
|
1
|
3
|
3
|
9
|
22
|
44
|
98
|
128
|
102
|
103
|
|
| Additional Paid In Capital |
4
|
4
|
4
|
2
|
2
|
50
|
50
|
51
|
49
|
48
|
48
|
|
| Total Equity |
4
N/A
|
5
+29%
|
7
+34%
|
7
+2%
|
13
+88%
|
74
+469%
|
96
+30%
|
151
+56%
|
180
+19%
|
152
-15%
|
153
+0%
|
|
| Total Liabilities & Equity |
18
N/A
|
23
+30%
|
29
+29%
|
56
+91%
|
77
+36%
|
147
+91%
|
194
+33%
|
321
+65%
|
396
+23%
|
363
-8%
|
313
-14%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
20
|
20
|
20
|
20
|
22
|
22
|
22
|
22
|
22
|
22
|
|
Switch to:
Switch to:
See Also
Discover More
